The trial attained both of those its Most important endpoints, with semaglutide 2.four mg demonstrating statistically sizeable and top-quality improvements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without having worsening of liver fibrosis